Title: | Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors |
Authors: | Maekawa, Naoya Browse this author →KAKEN DB |
Konnai, Satoru Browse this author →KAKEN DB |
Asano, Yumie Browse this author |
Otsuka, Takumi Browse this author |
Aoki, Eri Browse this author |
Takeuchi, Hiroto Browse this author |
Kato, Yukinari Browse this author |
Kaneko, Mika K. Browse this author |
Yamada, Shinji Browse this author |
Kagawa, Yumiko Browse this author |
Nishimura, Maki Browse this author |
Takagi, Satoshi Browse this author |
Deguchi, Tatsuya Browse this author |
Ohta, Hiroshi Browse this author |
Nakagawa, Takayuki Browse this author |
Suzuki, Yasuhiko Browse this author →KAKEN DB |
Okagawa, Tomohiro Browse this author →KAKEN DB |
Murata, Shiro Browse this author →KAKEN DB |
Ohashi, Kazuhiko Browse this author →KAKEN DB |
Issue Date: | 26-Jan-2023 |
Publisher: | PLOS |
Journal Title: | PLoS ONE |
Volume: | 18 |
Issue: | 1 |
Start Page: | e0281143 |
Publisher DOI: | 10.1371/journal.pone.0281143 |
Abstract: | Spontaneous tumors are a major cause of death in cats. Treatment of human tumors has progressed dramatically in the past decade, partly due to the success of immunotherapies using immune checkpoint inhibitors, such as anti-programmed death 1 (PD-1) and anti-PD-ligand 1 (PD-L1) antibodies. However, little is known about the PD-1 pathway and its association with tumor disease in cats. This study investigated the applicability of anti-PD-1/PD-L1 therapy in feline tumors. We first determined the complete coding sequence of feline PD-L1 and PD-L2, and found that the deduced amino acid sequences of feline PD-L1/PD-L2 share high sequence identities (66-83%) with orthologs in other mammalian species. We prepared recombinant feline PD-1, PD-L1, and PD-L2 proteins and confirmed receptor-ligand binding between PD-1 and PD-L1/PD-L2 using flow cytometry. Next, we established an anti-feline PD-L1 monoclonal antibody (clone CL1Mab-7) to analyze the expression of PD-L1. Flow cytometry using CL1Mab-7 revealed the cell surface expression of PD-L1 in a feline macrophage (Fcwf-4) and five mammary adenocarcinoma cell lines (FKNp, FMCm, FYMp, FONp, and FONm), and showed that PD-L1 expression was upregulated by interferon-gamma stimulation. Finally, immunohistochemistry using CL1Mab-7 also showed PD-L1 expression in feline squamous cell carcinoma (5/5, 100%), mammary adenocarcinoma (4/5, 80%), fibrosarcoma (5/5, 100%), and renal cell carcinoma (2/2, 100%) tissues. Our results strongly encourage further investigations of the PD-1/PD-L1 pathway as a potential therapeutic target for feline tumors. |
Type: | article |
URI: | http://hdl.handle.net/2115/89157 |
Appears in Collections: | 獣医学院・獣医学研究院 (Graduate School of Veterinary Medicine / Faculty of Veterinary Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|